IL202091A0 - Methods of treating cognitive disorders by inhibition of gpr12 - Google Patents
Methods of treating cognitive disorders by inhibition of gpr12Info
- Publication number
- IL202091A0 IL202091A0 IL202091A IL20209109A IL202091A0 IL 202091 A0 IL202091 A0 IL 202091A0 IL 202091 A IL202091 A IL 202091A IL 20209109 A IL20209109 A IL 20209109A IL 202091 A0 IL202091 A0 IL 202091A0
- Authority
- IL
- Israel
- Prior art keywords
- gpr12
- inhibition
- methods
- cognitive disorders
- treating cognitive
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93816307P | 2007-05-15 | 2007-05-15 | |
| PCT/US2008/063804 WO2008144453A1 (en) | 2007-05-15 | 2008-05-15 | Methods of treating cognitive disorders by inhibition of gpr12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL202091A0 true IL202091A0 (en) | 2010-06-16 |
Family
ID=40122145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL202091A IL202091A0 (en) | 2007-05-15 | 2009-11-12 | Methods of treating cognitive disorders by inhibition of gpr12 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7968524B2 (https=) |
| EP (1) | EP2162137B1 (https=) |
| JP (1) | JP2010527375A (https=) |
| KR (1) | KR20100029079A (https=) |
| CN (1) | CN101808647A (https=) |
| AU (1) | AU2008254905A1 (https=) |
| BR (1) | BRPI0811625A2 (https=) |
| CA (1) | CA2684920A1 (https=) |
| IL (1) | IL202091A0 (https=) |
| MX (1) | MX2009012316A (https=) |
| WO (1) | WO2008144453A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201404913QA (en) | 2009-04-09 | 2014-11-27 | Cognition Therapeutics Inc | Inhibitors of cognitive decline |
| RU2012107457A (ru) | 2009-07-31 | 2013-09-10 | Когнишн Терапьютикс, Инк. | Ингибиторы ухудшения когнитивных способностей |
| US20130071330A1 (en) * | 2010-02-26 | 2013-03-21 | Susan Catalano | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| US9499462B2 (en) | 2011-02-02 | 2016-11-22 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
| DK3099296T3 (en) | 2014-01-31 | 2019-04-15 | Cognition Therapeutics Inc | ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE |
| EP3634394B1 (en) | 2017-05-15 | 2025-12-24 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
| BR102022009685A2 (pt) * | 2022-05-18 | 2023-11-28 | Fundação Oswaldo Cruz | Método para triagem de fármacos ou substâncias com potencial neuroprotetor, kit para triagem de fármacos ou substâncias, e, uso de um painel de genes |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020317A (en) | 1993-02-19 | 2000-02-01 | Nippon Shinyaku Co. Ltd. | Glycerol derivative, device and pharmaceutical composition |
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
| US5877399A (en) * | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| CA2187626C (en) | 1994-04-13 | 2009-11-03 | Michael G. Kaplitt | Aav-mediated delivery of dna to cells of the nervous system |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| US6653086B1 (en) * | 1998-04-14 | 2003-11-25 | Arena Pharmaceuticals, Inc. | Endogenous constitutively activated G protein-coupled orphan receptors |
| WO2001048483A2 (en) * | 1999-12-10 | 2001-07-05 | Astrazeneca Ab | Method for screening of appetite control agents |
| US20040224316A1 (en) * | 2000-08-10 | 2004-11-11 | Tully Timothy P. | Augmented cognitive training |
| US20060247194A1 (en) | 2000-08-30 | 2006-11-02 | Sirna Therapeutics , Inc. | Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) |
| US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US6586524B2 (en) | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| US20040023384A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 12 expression |
| US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| WO2004014933A1 (en) | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
| WO2004038407A2 (en) * | 2002-10-24 | 2004-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) |
| US7829694B2 (en) * | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| US20070104688A1 (en) | 2003-02-13 | 2007-05-10 | City Of Hope | Small interfering RNA mediated transcriptional gene silencing in mammalian cells |
| CA2539127A1 (en) * | 2003-09-19 | 2005-03-31 | Paradigm Therapeutics Limited | Receptor |
| WO2005103713A2 (en) | 2004-04-20 | 2005-11-03 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
-
2008
- 2008-05-15 KR KR1020097024747A patent/KR20100029079A/ko not_active Withdrawn
- 2008-05-15 WO PCT/US2008/063804 patent/WO2008144453A1/en not_active Ceased
- 2008-05-15 BR BRPI0811625-3A2A patent/BRPI0811625A2/pt not_active IP Right Cessation
- 2008-05-15 CA CA002684920A patent/CA2684920A1/en not_active Abandoned
- 2008-05-15 JP JP2010508596A patent/JP2010527375A/ja active Pending
- 2008-05-15 MX MX2009012316A patent/MX2009012316A/es unknown
- 2008-05-15 US US12/121,731 patent/US7968524B2/en not_active Expired - Fee Related
- 2008-05-15 AU AU2008254905A patent/AU2008254905A1/en not_active Abandoned
- 2008-05-15 CN CN200880023965A patent/CN101808647A/zh active Pending
- 2008-05-15 EP EP08755619.7A patent/EP2162137B1/en not_active Not-in-force
-
2009
- 2009-11-12 IL IL202091A patent/IL202091A0/en unknown
-
2011
- 2011-06-27 US US13/169,739 patent/US20110281936A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2162137A4 (en) | 2011-06-08 |
| AU2008254905A1 (en) | 2008-11-27 |
| US7968524B2 (en) | 2011-06-28 |
| US20090022667A1 (en) | 2009-01-22 |
| US20110281936A1 (en) | 2011-11-17 |
| MX2009012316A (es) | 2009-12-03 |
| EP2162137B1 (en) | 2016-11-23 |
| KR20100029079A (ko) | 2010-03-15 |
| EP2162137A1 (en) | 2010-03-17 |
| CN101808647A (zh) | 2010-08-18 |
| WO2008144453A1 (en) | 2008-11-27 |
| JP2010527375A (ja) | 2010-08-12 |
| WO2008144453A9 (en) | 2010-03-18 |
| CA2684920A1 (en) | 2008-11-27 |
| BRPI0811625A2 (pt) | 2014-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0703909D0 (en) | Treatment of anxiety disorders | |
| ZA201204658B (en) | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | |
| PL2391650T3 (pl) | Sposoby leczenia dny | |
| IL217901A0 (en) | Treatment of bdnf-related disorders using laquninimod | |
| IL208513A0 (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| EP2142206A4 (en) | METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESSES | |
| GB0904287D0 (en) | Compounds for the treatment of metabolic disorders | |
| ZA201107449B (en) | Compounds for the treatment of metabolic disorders | |
| GB0904284D0 (en) | Compounds for the treatment of metabolic disorders | |
| IL202091A0 (en) | Methods of treating cognitive disorders by inhibition of gpr12 | |
| EP2331097A4 (en) | METHOD FOR TREATING CNS DISEASES | |
| ZA201204391B (en) | Compounds for the treatment of neurologic disorders | |
| ZA201000384B (en) | Treatment of vasomotor symptoms | |
| WO2009120799A9 (en) | Methods of treating fibrotic disorders | |
| GB0809476D0 (en) | Treatment of neurodegenerative disorders | |
| ZA201200124B (en) | Method of treating age related disorders | |
| EP2164494A4 (en) | Methods of Treatment | |
| IL210558A0 (en) | Treatment of anxiety disorders | |
| AU2009223851A8 (en) | Methods of treating hyperacidic disorders | |
| HK1146654A (en) | Methods of treating cognitive disorders by inhibition of gpr12 | |
| GB0819446D0 (en) | Treatment of inflammatory disorders | |
| EP2124957A4 (en) | METHOD FOR THE TREATMENT OF VITAL DISEASES | |
| ZA201100325B (en) | Treatment of anxiety disorders | |
| HK1174786A (en) | Compounds for the treatment of neurologic disorders | |
| IL208831A0 (en) | Methods of treating ophthalmic disorders |